Abstract
Introduction Neuropathologic assessment is the current "gold standard" for evaluating the Alzheimer's disease (AD), but there is no consensus on the methods used. Methods Fifteen unstained slides (8 brain regions) from each of the 14 cases were prepared and distributed to 10 different National Institute on Aging AD Centers for application of usual staining and evaluation following recently revised guidelines for AD neuropathologic change. Results Current practice used in the AD Centers Program achieved robustly excellent agreement for the severity score for AD neuropathologic change (average weighted κ =.88, 95% confidence interval: 0.77-0.95) and good-to-excellent agreement for the three supporting scores. Some improvement was observed with consensus evaluation but not with central staining of slides. Evaluation of glass slides and digitally prepared whole-slide images was comparable. Discussion AD neuropathologic evaluation as performed across AD Centers yields data that have high agreement with potential modifications for modest improvements.
| Original language | English |
|---|---|
| Pages (from-to) | 164-169 |
| Number of pages | 6 |
| Journal | Alzheimer's and Dementia |
| Volume | 12 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1 2016 |
Bibliographical note
Publisher Copyright:© 2016 The Alzheimer's Association.
Funding
This work was supported by the following grants from the National Institute on Aging , National Institutes of Health : the, National Alzheimer's Coordinating Center ( U01 AG016976 ), Alzheimer's Disease Centers ( P50 AG05133 , P50 AG05134 , P50 AG05136 , P50 AG05681 , P30 AG10161 , P30 AG10124 , P30 AG13854 , P50 AG16570 , P30 AG19610 , and P30 AG28383 ), and P01 AG03991 . We thank Dr Kathleen Montine for editorial assistance. This work was supported by the following grants from the National Institute on Aging, National Institutes of Health: the, National Alzheimer''s Coordinating Center (U01 AG016976), Alzheimer''s Disease Centers (P50 AG05133, P50 AG05134, P50 AG05136, P50 AG05681, P30 AG10161, P30 AG10124, P30 AG13854, P50 AG16570, P30 AG19610, and P30 AG28383), and P01 AG03991. We thank Dr Kathleen Montine for editorial assistance.
| Funders | Funder number |
|---|---|
| Alzheimer's Disease Centers | P50 AG05133, P30 AG10124, P50 AG16570, P50 AG05134, P30 AG28383, P50 AG05136, P30 AG13854, P30 AG19610, P01 AG03991, P30 AG10161, P50 AG05681 |
| National Alzheimer's Coordinating Center | U01 AG016976 |
| National Institutes of Health (NIH) | |
| National Institute on Aging | P50AG005134, P01AG003991 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Alzheimer's disease
- Methods
- Multisite
- Neuropathology
- Whole-slide imaging
ASJC Scopus subject areas
- Epidemiology
- Health Policy
- Developmental Neuroscience
- Clinical Neurology
- Geriatrics and Gerontology
- Cellular and Molecular Neuroscience
- Psychiatry and Mental health
Fingerprint
Dive into the research topics of 'Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver